Skip to content

Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06373926
Acronym
MONOCYTAN
Enrollment
60
Registered
2024-04-18
Start date
2025-02-05
Completion date
2026-03-31
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiphospholipid Syndrome

Keywords

annexin A2, antiphospholipid syndrome, monocytes

Brief summary

Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, plays a pivotal role in regulation of fibrinolysis in vitro and in vivo and has been identified as a new autoantigen in antiphospholipid syndrome (APS). ANXA2 can exist as a monomer or a heterotetrameric complex with S100A10 protein. The aim of this study was to evaluate the cell membrane expression of ANXA2 on circulating monocytes in APS by flow cytometry. Several pathogenic mechanisms are involved in APS such as activation of endothelial cells, platelets and monocytes, inhibition of the natural anticoagulant protein C/protein S pathway, activation of the complement system and also impairment of fibrinolysis. Annexin A2 which hits binding partner S100A10, ANXA2 forms a cell surface complex that regulates generation of plasmin. ANXA2 is involved in the pathogenesis of APS-associated through several possible mechanisms. Human peripheral blood monocytes represent the major circulating ANXA2-expressing cell and ANXA2-mediated assembly of plasminogen and tissue activator of plasminogen (tPA) on monocyte/macrophages contributes to plasmin generation. Thus the investigators could suppose that decrease of cell membrane expression of ANXA2 on circulating monocytes represent a new pathogenic mechanism in APS.

Interventions

BIOLOGICALblood withdrawal

blood withdrawal

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* APS patients who fulfilled the revised criteria for APS

Exclusion criteria

* Patients less than 18 years old * Solid and hematological malignancies * Other autoimmune diseases * Cirrhosis

Design outcomes

Primary

MeasureTime frame
Cell membrane expression rate of ANXA2 on circulating monocytes in APS1 hour

Secondary

MeasureTime frame
cell membrane expression of ANXA2 and S100A10 in APS patients1 hour
Cellular expression of ANXA2 and S100A10 in APS patients1 hour

Countries

France

Contacts

Primary ContactValéry Salle, MD
salle.valery@chu-amiens.fr03 22 66 82 30

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026